The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Medically reviewed by Anita C. Chandrasekaran, MD Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and ...

Psoriatic arthritis can affect any joint in the body ... Your doctor will work to rule these out when making a diagnosis. There are many treatment options available for PsA.

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Methotrexate (MTX) is a drug that has been used to treat psoriatic arthritis (PsA) for more than 40 years. Alone or in combination with other therapies, MTX is considered a first-line treatment ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Aggressive treatment of arthritis often involves ... Approved to treat certain forms of inflammatory arthritis such as psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.